Your browser doesn't support javascript.
loading
Identifying a response for the systemic lupus erythematosus disease activity glucocorticoid index (SLEDAI-2KG).
Touma, Zahi; Gladman, Dafna D; Zandy, Moe; Su, Jiandong; Anderson, Nicole; Urowitz, Murray B.
Afiliação
  • Touma Z; University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.
  • Gladman DD; University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.
  • Zandy M; University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.
  • Su J; University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.
  • Anderson N; University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.
  • Urowitz MB; University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.
Artigo em Inglês | MEDLINE | ID: mdl-32433815
ABSTRACT

OBJECTIVE:

To compare the performance of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and SLEDAI-2K glucocorticoids (SLEDAI-2KG) indices in identifying responders to standard of care (SoC) therapy.

METHODS:

Data from adult patients seen between 1995-2018 at the University of Toronto Lupus Clinic was analyzed. Patients with active disease (SLEDAI-2K ≥6) and on prednisone ≥ 5 mg/day, and with a follow up visit at 9 months were studied. Response to SoC therapy, at first follow up visit, was assessed by SLEDAI-2K and SLEDAI-2KG. The performances of SLEDAI-2K and SLEDAI-2KG were compared using a cut-off point of 4.

RESULTS:

In a cohort of 188, the majority were female (86.0%) and Caucasian (47.9%). Of 188 patients, 145 (77.1%) were responders and had a decrease in SLEDAI-2K score of ≥4. SLEDAI-2KG identified 142 (97.9%) responders of SLEDAI-2K responders. More importantly, SLEDAI-2KG identified 11 (25.6%) additional responders among SLEDAI-2K non-responders (n=43). This resulted from the ability of SLEDAI-2KG to account for the decrease in glucocorticoids dose.

CONCLUSIONS:

SLEDAI-2KG provides a novel concept for the assessment of lupus disease activity while accounting for glucocorticoids dose to reflect on disease activity overall at a particular visit. SLEDAI-2KG accounts for the disease activity for each descriptor while also accounting for the current glucocorticoids dose. SLEDAI-2KG adds one additional variable (corticosteroid dose) to SLEDAI-2K which could alter response rates in drug trials and observational studies.
Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Tipo de estudo: Estudo prognóstico Idioma: Inglês Assunto da revista: Reumatologia Ano de publicação: 2020 Tipo de documento: Artigo País de afiliação: Canadá

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Tipo de estudo: Estudo prognóstico Idioma: Inglês Assunto da revista: Reumatologia Ano de publicação: 2020 Tipo de documento: Artigo País de afiliação: Canadá